title: Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
abstract: Manufacturers of human therapeutic proteins derived from biological sources continuously strive to improve the pathogen safety profiles of these products. Efforts to improve pathogen safety margins for these biological products are directed towards several areas within the manufacturing processes including: (a) sourcing and screening of raw materials (b) determining the potential for manufacturing processes to reduce pathogen titres, and (c) incorporating methods designed specifically to remove or inactivate contaminating pathogens. Methods that could potentially reduce pathogen titres are a major focus for many manufacturers. In general, these methods are grouped into two categories, pathogen clearance and pathogen inactivation. Assessments are performed on small-scale, laboratory simulations of the manufacturing process of interest that are spiked with a known amount of a selected pathogen. These studies provide estimates of the potential for a process step to remove or inactivate a particular pathogen. There are several pathogen clearance/inactivation methods that are inherent in manufacturing processes, however, some methods are intentionally incorporated into manufacturing for the sole purpose of reducing putative pathogen titres. Not only are well-known pathogens such as viruses targeted, but also suspected pathogens such as those associated with the transmissible spongiform encephalopathies (TSEs). The production processes for the isolation of several biological products, including recombinant KOGENATE Bayer (Kogenate FS), have been evaluated for the ability to reduce pathogen titres and/or have been designed to incorporate methods for reducing potential pathogen safety risks. Several processing steps with the potential to reduce pathogen titres have been identified.
authors.affiliation: Department of Pathogen Safety & Research/Biological Products, Bayer Corporation, Research Triangle Park, NC, USA. doug.lee.b@bayer.com
authors.forename: D C
authors.initials: DC
authors.lastname: Lee
authors.forename: J L A
authors.initials: JL
authors.lastname: Miller
authors.forename: S R
authors.initials: SR
authors.lastname: Petteway
mesh_terms: D001688:Biological Products / Q000592:standards*; D017848:Blood-Borne Pathogens; D003257:Consumer Product Safety / Q000592:standards*; D007562:Creutzfeldt-Jakob Syndrome / Q000517:prevention & control / Q000635:transmission; D004340:Drug Contamination / Q000517:prevention & control*; D005169:Factor VIII / Q000592:standards*; D006801:Humans; D011786:Quality Control; D013678:Technology, Pharmaceutical / Q000592:standards*; D014777:Virus Diseases / Q000517:prevention & control / Q000635:transmission
chemical_list: D001688:Biological Products; C078147:F8 protein, human; D005169:Factor VIII